Minimal procedure-related toxicity and mortality.

Minimal risks of late effects in young individuals (e.g. growth retardation; endocrine adenopathies; sterility, etc).

For elderly individuals with AML and MDS.

For patients with poor performance status.

For continuous GVL effects by DLI in mixed chimeras.

Transient mixed chimerism may allow better control of GVHD (yet to be proven).